Literature DB >> 11342440

Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo.

C Y Koh1, B R Blazar, T George, L A Welniak, C M Capitini, A Raziuddin, W J Murphy, M Bennett.   

Abstract

Subsets of natural killer (NK) cells are characterized by the expression of inhibitory and/or stimulatory receptors specific for major histocompatibility complex (MHC) class I determinants. In mice, these include the Ly49 family of molecules. One mechanism by which tumor cells may evade NK cell killing is by expressing the appropriate MHC class I and binding inhibitory Ly49 receptors. Therefore, the question of whether blocking the interaction between the Ly49 inhibitory receptors on NK and MHC class I cells on tumor cells augments antitumor activity was investigated. Blockade of Ly49C and I inhibitory receptors using F(ab')(2) fragments of the 5E6 monoclonal antibody (mAb) resulted in increased cytotoxicity against syngeneic tumors and decreased tumor cell growth in vitro. The effect of 5E6 F(ab')(2) was specific for the MHC of the tumor, as the use of F(ab')(2) of the mAb against Ly49G2 failed to increase NK activity. Treatment of leukemia-bearing mice with 5E6 F(ab')(2) fragments or adoptive transfer of NK cells treated ex vivo with the F(ab')(2) resulted in significant increases in survival. These results demonstrate that blockade of NK inhibitory receptors enhances antitumor activity both in vitro and in vivo, suggesting that NK inhibitory receptors can be responsible for diminishing antitumor responses. Therefore, strategies to block inhibitory receptors may be of potential use in increasing the efficacy of immunotherapy. (Blood. 2001;97:3132-3137)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342440     DOI: 10.1182/blood.v97.10.3132

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

Review 1.  Natural killer cell tolerance: control by self or self-control?

Authors:  Baptiste N Jaeger; Eric Vivier
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-03-01       Impact factor: 10.005

Review 2.  Combination strategies to enhance antitumor ADCC.

Authors:  Holbrook E Kohrt; Roch Houot; Aurélien Marabelle; Hearn Jay Cho; Keren Osman; Matthew Goldstein; Ronald Levy; Joshua Brody
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

3.  Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC.

Authors:  Isabel Barao; Maite Alvarez; Erik Ames; Mark T Orr; Heather E Stefanski; Bruce R Blazar; Lewis L Lanier; Stephen K Anderson; Doug Redelman; William J Murphy
Journal:  Blood       Date:  2011-04-15       Impact factor: 22.113

Review 4.  Natural killer cells in immunodefense against infective agents.

Authors:  Nicolas Zucchini; Karine Crozat; Thomas Baranek; Scott H Robbins; Marcus Altfeld; Marc Dalod
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

Review 5.  Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia.

Authors:  Junji Tanaka; Masahiro Asaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

6.  Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo.

Authors:  Caroline Sola; Pascale André; Céline Lemmers; Nicolas Fuseri; Cécile Bonnafous; Mathieu Bléry; Nicolai R Wagtmann; François Romagné; Eric Vivier; Sophie Ugolini
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-26       Impact factor: 11.205

7.  Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.

Authors:  Camilla Jandus; Kayluz Frias Boligan; Obinna Chijioke; He Liu; Meike Dahlhaus; Thomas Démoulins; Christoph Schneider; Marc Wehrli; Robert E Hunger; Gabriela M Baerlocher; Hans-Uwe Simon; Pedro Romero; Christian Münz; Stephan von Gunten
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

8.  Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

Authors:  Holbrook E Kohrt; Ariane Thielens; Aurelien Marabelle; Idit Sagiv-Barfi; Caroline Sola; Fabien Chanuc; Nicolas Fuseri; Cécile Bonnafous; Debra Czerwinski; Amanda Rajapaksa; Erin Waller; Sophie Ugolini; Eric Vivier; François Romagné; Ronald Levy; Mathieu Bléry; Pascale André
Journal:  Blood       Date:  2013-12-10       Impact factor: 22.113

9.  Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.

Authors:  Anna Kruschinski; Andreas Moosmann; Isabel Poschke; Håkan Norell; Markus Chmielewski; Barbara Seliger; Rolf Kiessling; Thomas Blankenstein; Hinrich Abken; Jehad Charo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-05       Impact factor: 11.205

Review 10.  Immune-based therapeutics for pediatric cancer.

Authors:  Christian M Capitini; Crystal L Mackall; Alan S Wayne
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.